CD8A and neoplasm: Additionally, SMI402, which effectively inhibits TIM-3 from binding to CEACAM-1, HMGB-1, and PtdSer [229], has demonstrated its capacity to suppress tumor growth by promoting the infiltration and activation of CD8+ T cells and NK cell at the tumor site [229].